enGene (NASDAQ:ENGN) Now Covered by HC Wainwright

Investment analysts at HC Wainwright assumed coverage on shares of enGene (NASDAQ:ENGN - Get Free Report) in a report released on Monday, MarketBeat.com reports. The brokerage set a "buy" rating and a $25.00 price target on the stock. HC Wainwright's target price indicates a potential upside of 319.46% from the stock's previous close.

Several other analysts have also weighed in on ENGN. JMP Securities reissued a "market outperform" rating and set a $18.00 price objective on shares of enGene in a report on Friday, December 6th. Raymond James began coverage on shares of enGene in a report on Wednesday, November 27th. They issued an "outperform" rating and a $23.00 price target on the stock. Oppenheimer restated an "outperform" rating and issued a $30.00 price objective on shares of enGene in a research note on Tuesday, September 24th. Citizens Jmp upgraded shares of enGene to a "strong-buy" rating in a research report on Monday, November 18th. Finally, Morgan Stanley reissued an "overweight" rating and issued a $40.00 price target on shares of enGene in a research report on Wednesday, September 11th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, enGene has an average rating of "Buy" and a consensus price target of $29.78.

enGene Stock Performance

enGene stock traded up $0.13 during mid-day trading on Monday, reaching $5.96. The company had a trading volume of 131,078 shares, compared to its average volume of 118,111. The company has a 50 day moving average of $8.13 and a 200-day moving average of $7.80. The firm has a market cap of $263.53 million, a price-to-earnings ratio of -10.28 and a beta of -0.78. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09. enGene has a 52 week low of $4.42 and a 52 week high of $18.40.

enGene (NASDAQ:ENGN - Get Free Report) last released its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.06. On average, sell-side analysts expect that enGene will post -1.52 EPS for the current fiscal year.

Insider Transactions at enGene

In other enGene news, major shareholder Growth Opportunities F. Forbion bought 341,332 shares of the firm's stock in a transaction dated Monday, September 30th. The shares were bought at an average price of $6.34 per share, for a total transaction of $2,164,044.88. Following the completion of the acquisition, the insider now owns 2,400,791 shares of the company's stock, valued at approximately $15,221,014.94. This trade represents a 16.57 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Ronald Harold Wilfred Cooper purchased 10,000 shares of the business's stock in a transaction that occurred on Friday, September 27th. The stock was acquired at an average cost of $5.70 per share, with a total value of $57,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 10,000 shares of the company's stock, valued at $57,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 420,965 shares of company stock valued at $2,651,103. Corporate insiders own 13.70% of the company's stock.

Hedge Funds Weigh In On enGene

A number of large investors have recently modified their holdings of ENGN. SR One Capital Management LP acquired a new stake in shares of enGene in the second quarter valued at approximately $4,715,000. Logos Global Management LP increased its stake in shares of enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company's stock valued at $11,316,000 after buying an additional 400,000 shares during the period. Wolverine Asset Management LLC bought a new stake in shares of enGene during the third quarter worth $37,000. Point72 Asset Management L.P. lifted its stake in shares of enGene by 1,410.3% during the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company's stock valued at $4,376,000 after acquiring an additional 619,100 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company's stock valued at $7,854,000 after acquiring an additional 389,918 shares during the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.